• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to project page

2021 Fiscal Year Final Research Report

RNA vaccine that exerts antitumor effect via non-canonical antigen presentation pathway

Research Project

  • PDF
Project/Area Number 19K07782
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Review Section Basic Section 50020:Tumor diagnostics and therapeutics-related
Research InstitutionJikei University School of Medicine

Principal Investigator

ITO MASAKI  東京慈恵会医科大学, 医学部, 講師 (80297366)

Co-Investigator(Kenkyū-buntansha) 小井戸 薫雄  東京慈恵会医科大学, 医学部, 教授 (70266617)
Project Period (FY) 2019-04-01 – 2022-03-31
KeywordsRNAワクチン / ワクチン / がん / ネオエピトープ / ネオアンチゲン / 抗原提示経路
Outline of Final Research Achievements

We have identified an "Artificial Designed Sequence (ADS)" peptide sequence structure that specifies the fate of the antigen to go through the non-canonical antigen presentation pathway (ER-Golgi independent pathway). This ADS and neoepitope of cancer cells were incorporated into the framework of mRNA to prepare an RNA vaccine by implanting a cap analog structure, pseudouridine, and poly-A tail into mRNA using an in vitro transcription system. The immunostimulatory ability of the RNA vaccine was quantitatively evaluated using reporter T cells with neoepitope recognition-specific TCR. It was clarified that the ADS-containing RNA vaccine can efficiently exert cell-mediated immunity induction.

Free Research Field

腫瘍免疫学

Academic Significance and Societal Importance of the Research Achievements

新型コロナ感染症の世界的パンデミックが起こり、様々な抗原に対して迅速にワクチン製造が可能なRNAワクチンの有効性が実証された。しかしながら、現状のRNAワクチンは抗原の全長mRNAを用いており、今後さらにワクチン効力の改善が求められる。我々の開発しているnon-canonical抗原提示経路を経て抗原提示するワクチンは、RNAワクチンに新たな機能を付与する事が期待される。

URL: 

Published: 2023-01-30  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi